Research > Team I:Molecular Mechanisms of Diseases and Target



Name Xue Xue
Research Area Theranostic Nanomedicine
Tel
E-mail xuexue19861007@163.com
Brief
Introduction
Dr. Xue Xue obtained her Ph.D at National Center for Nanoscience and Technologies, Chinese Academy of Sciences, with her mentor Dr. Xing-jie Liang. From 2012 to 2014, she studied in New York University as a visiting scholar. Then she was an assistant professor with Dr. Hong Zhang at National Key Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences. Dr. Xue is currently a principle investigator in State Key Laboratory of Medicinal Chemical Biology/College of Pharmacy, and lab chief of Laboratory of Theranostic Nanomedicine in Nankai University. In recent five years, she has authored over 15 SCI-indexed papers with total IF > 150.She has 7 published papers as first/corresponding author with total IF > 90, and the average IF is over 13, including Nature Nanotechnology, Molecular Cell, Nano Letters, ACS Nano, Small, etc.. She has also applied 2 nanomedicine-related authorized patents

Xue’s lab has long been engaged in the nanomedicine for their biological activation, structure-effect relationship, biological safety evaluation and the further mechanisms, committing to the application of nanomaterials in biomedical field, especially in animal model. The study included a number of major human diseases (cancer, Alzheimer's disease, drug addiction), and in-depth exploration of various mechanisms (autophagy, nerve regeneration, tumor resistance, etc.).
Welcome to the graduate students or postdocs to join Xue’s lab with the major of cell biology, medicine, pharmacy, materials science, and chemistry!
Resent Publications (in 5 years)
Selected Publications:
1.         Wang Z(#), Miao GY(#), Xue X(#), Guo XY, Yuan CZ, Wang ZY, Zhang GM, Chen YY, Feng D, Hu JJ, Zhang H(*). The Vici Syndrome Protein EPG5 Is a Rab7 Effector that Determines the Fusion Specificity of Autophagosomes with Late Endosomes/Lysosomes. Mol. Cell, 2016, 63(5):781-795. IF 13.958
2.         Xue X(#), Yang JY(#), He Y(#), Wang LR, Liu P, Yu LS, Bi GH, Zhu MM, Liu YY, Xiang RW, Yang XT, Fan XY, Wang XM, Qi J, Zhang HJ, Wei T, Cui W, Ge GL, Xi ZX(*), Wu CF(*), Liang XJ(*). Aggregated Single-Walled Carbon Nanotubes Attenuate the Behavioural and Neurochemical Effects of Methamphetamine in Mice. Nat. Nanotech., 2016, 11(7): 613-620. IF 35.267
3.         Xue X, Wang LR, Sato Y, Jiang Y, Berg M, Yang DS, Nixon RA(*), Liang XJ(*). Single-Walled Carbon Nanotubes Alleviate Autophagic/Lysosomal Defects in Primary Glia from a Mouse Model of Alzheimer’s Disease. Nano Lett., 2014, 14(9): 5110-5117. IF 13.779
4.         Wang LR(#), Xue X(#), Hu XM, Wei MY, Zhang CQ, Ge GL(*), Liang XJ(*). Structure-Dependent Mitochondrial Dysfunction and Hypoxia Induced with Single-Walled Carbon Nanotubes. Small, 2014, 10(14): 2859-2869. IF 8.315
5.         Xue X, Hall MD, Zhang Q, Wang PC, Gottesman MM(*), Liang XJ(*). Nanoscale Drug Delivery Platforms Overcome Platinum-Based Resistance in Cancer Cells Due to Abnormal Membrane Protein Trafficking. ACS Nano, 2013, 7(12):10452-10464. IF 13.334
6.         Xue X, You S, Zhang Q, Wu Y, Zou GZ, Wang PC, Zhao YL, Xu Y, Jia L, Zhang XN, Liang XJ(*).Mitaplatin Increases Sensitivity of Tumor Cells to Cisplatin by Inducing Mitochondrial Dysfunction. Mol. Pharm., 2012, 9(3):634-644.IF 4.342
7.         Yang JY, Xue X, Tian H, Wang XX, Dong YX, Wang F, Zhao YN, Wu CF(*). Role of Microglia in Ethanol-Induced Neurodegenerative Disease: Pathological and Behavioral Dysfunction at Different Developmental Stages. Pharmacol. & Ther., 2014, 144(3): 321-337. IF 11.0 
Books
Xue X, Liang XJ. Nanomedicine, Nanostructure Science and Technology. Chapter 6: Multifunctional Nanoparticles for Theranostics and Imaging, Springer 2014, 101-115.